PSYCH Symposium Rebrands as Mind Forward for Another London Event

LONDON – The organizers of Europe’s established psychedelic medicine conference have rebranded the platform and expanded its focus. The new identity, Mind Forward, will host a one-day symposium in London later this year.

PSYCH has transitioned into Mind Forward after more than six years of programming centered on psychedelic research, policy and care. The shift keeps psychedelics as a core subject while adding coverage of biohacking, mind longevity, digital therapeutics, mental health technology and CNS therapies. Mind Forward describes itself as a platform for mental health innovation that brings together patients, researchers, clinicians, investors and policymakers.

The inaugural Mind Forward is scheduled for December 1, 2026, Ministry of Sound, London. Full details on the venue and speaker lineup have not yet been released. Organizers note that the event continues the tradition of the previous PSYCH Symposiums, which were produced by Prohibition Partners in partnership with Drug Science and held at Conway Hall.

Prohibition Partners, the team behind Cannabis Europa and other industry conferences, presents and powers the new platform. Past PSYCH events featured speakers like Professor David Nutt of Imperial College London and Drug Science, along with researchers and clinicians from University College London and other institutions. Mind Forward has indicated that similar expertise will inform the expanded program.

The rebrand follows the December 2025 PSYCH Symposium, which drew more than 250 attendees to discuss clinical data, regulation and access to psychedelic-assisted therapies. Organizers say the broader scope reflects the wider set of tools and approaches now under discussion in mental health care.

The move from a psychedelic-focused symposium to a wider mental-health innovation platform mirrors the field’s growing interest in complementary technologies and treatments. The rebranded London gathering will offer a view of how the expanded agenda takes shape and which topics draw the strongest engagement from clinicians, researchers and investors.